Update of Antiplatelet Therapy in Patients Without Known Cardiovascular Disease

1. Aleksandric S, Tomasevic M, Dobric M, Beleslin B, Tasic M. Antitrombocitna terapija u sekundarnoj prevenciji. Srce i krvni sudovi 2011;30(4):224-233.Search in Google Scholar

2. Gurbel PA, Myat A, Kubica J, Tantry US. State of the art: Oral antiplatelet therapy. JRSM Cardiovasc Dis 2016;5:1-10.10.1177/2048004016652514Search in Google Scholar

3. Bhatt DL, Fox KA, Hacke W, et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354(16):1706-1717.10.1056/NEJMoa060989Search in Google Scholar

4. ISIS-2 trial. Second International Study of Infarct Survival) collaborative group. Randomized trial of intravenous streptokinase, oral aspirin, both, or either among 17 187 cases of suspected acute myocardial infarction: Lancet 1988;2(8607):349-360.Search in Google Scholar

5. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.10.1136/bmj.324.7329.71Search in Google Scholar

6. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.10.1136/bmj.308.6921.81Search in Google Scholar

7. Popma JJ, Ohman EM, Weitz J, et al. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest 2001;119(1 Suppl):321S-36S.10.1378/chest.119.1_suppl.321SSearch in Google Scholar

8. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a metaanalysis. Am J Med 2008;121(1):43–49.10.1016/j.amjmed.2007.10.002Search in Google Scholar

9. CAST: Randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) collaborative group. Lancet 1997; 349(9066):1641-1649.10.1016/S0140-6736(97)04010-5Search in Google Scholar

10. Miedema MD, Huguelet J, Virani SS. Aspirin for the Primary Prevention of Cardiovascular Disease: In Need of Clarity. Curr Atheroscler Rep 2016;18(1):4. doi: 10.1007/s11883-015-0555-0. Review.10.1007/s11883-015-0555-026753770Search in Google Scholar

11. ASCEND trial. A Study of Cardiovascular Events in Diabetes. Available from: http://www.ctsu.ox.ac.uk/ascend.Search in Google Scholar

12. De Berardis G, Sacco M, Evangelista V, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007;8:21.10.1186/1745-6215-8-21201477117725825Search in Google Scholar

13. Nelson MR, Reid CM, Ames DA, et al. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust 2008;189:105-109.10.5694/j.1326-5377.2008.tb01932.x18637782Search in Google Scholar

14. Bayer ARRIVE aspirin research study. Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE) Trial. Available from: http://www.arrive-study.com/EN/study.cfmSearch in Google Scholar

15. Halvorsen S, Andreotti F, ten Berg JM, et al. Aspirin therapy in primary cardiovascular disease prevention. A position paper of the European Society of Cardiology Working Group on Thrombosis. J Am Coll Cardiol 2014;64:319–327.10.1016/j.jacc.2014.03.049Open DOISearch in Google Scholar

16. Cheng JW. Updates in antiplatelet agents used in cardiovascular diseases. J Cardiovasc Pharmacol Ther 2013;18(6):514-524.10.1177/1074248413499971Search in Google Scholar

17. Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678): 1849-1860.10.1016/S0140-6736(09)60503-1Search in Google Scholar

18. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e637S–668S.10.1378/chest.141.4.1129cSearch in Google Scholar

19. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. J Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295(3):306-313.10.1001/jama.295.3.30616418466Search in Google Scholar

20. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;150(6):396-404.10.7326/0003-4819-150-6-200903170-0000819293072Search in Google Scholar

21. Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164(12):826-835.10.7326/M15-211227064261Search in Google Scholar

22. Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014;312:2510-2220. [PMID: 25401325] doi:10.1001/jama.2014.15690.10.1001/jama.2014.1569025401325Search in Google Scholar

23. Hernandez-Diaz S, Garcia Rodriguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006;4:22. [PMID: 16987411].10.1186/1741-7015-4-22159004416987411Search in Google Scholar

24. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002;106:388-391.10.1161/01.CIR.0000020190.45892.7512119259Search in Google Scholar

25. Effectiveness-based guidelines for the prevention of CVD in women - 2011 update. A guideline from the American Heart Association. Circulation 2011;123:1243-1262.10.1161/CIR.0b013e31820faaf8318214321325087Search in Google Scholar

26. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37:2315-2381.10.1093/eurheartj/ehw106498603027222591Search in Google Scholar

27. Lanas A, Polo-Tomas M, Casado-Arroyo R. The aspirin cardiovascular/gastrointestinal risk calculator - a tool to aid clinicians in practice. Aliment Pharmacol Ther. 2013;37: 738-748. [PMID: 23413984] doi:10.1111/apt.12240.10.1111/apt.1224023413984Search in Google Scholar

28. Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10:e0124653. [PMID:26061035] doi:10.1371/journal.pone.0124653.10.1371/journal.pone.0124653446257826061035Search in Google Scholar

29. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162:55-63. [PMID: 25560714] doi:10.7326/M14-0697.10.7326/M14-069725560714Search in Google Scholar

30. Belch J, MacCuish A, Campbell I, et al. Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840.10.1136/bmj.a1840265886518927173Search in Google Scholar

31. Ogawa H, NakayamaM, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300(18):2134–2141.10.1001/jama.2008.62318997198Search in Google Scholar

32. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010;303(9):841–848.10.1001/jama.2010.22120197530Search in Google Scholar

33. Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014;312(23):2510–2520.10.1001/jama.2014.1569025401325Search in Google Scholar

34. Bartolucci AA, Tendera M, Howard G. Metaanalysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2011;107:1796–1801.10.1016/j.amjcard.2011.02.32521481826Search in Google Scholar

35. Raju N, Sobieraj-Teague M, Hirsh J, et al. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011;124:621–629.10.1016/j.amjmed.2011.01.01821592450Search in Google Scholar

36. Berger JS, Lala A, Krantz MJ, et al. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a metaanalysis of randomized trials. Am Heart J 2011;162:115–124, e2.10.1016/j.ahj.2011.04.00621742097Search in Google Scholar

37. Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta- analysis of randomized controlled trials. Arch Intern Med 2012;172:209–16.10.1001/archinternmed.2011.62822231610Search in Google Scholar

38. De Berardis G, Sacco M, Strippoli GF, Pellegret al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531. doi: 10.1136/bmj.b4531.10.1136/bmj.b4531277438819897665Open DOISearch in Google Scholar

39. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes. A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation. Circulation. 2010;121:2694-2701.10.1161/CIR.0b013e3181e3b13320508178Search in Google Scholar